These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35593028)

  • 1. Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease.
    Shen J; Amari N; Zack R; Skrinak RT; Unger TL; Posavi M; Tropea TF; Xie SX; Van Deerlin VM; Dewey RB; Weintraub D; Trojanowski JQ; Chen-Plotkin AS
    Ann Neurol; 2022 Aug; 92(2):255-269. PubMed ID: 35593028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis.
    Posavi M; Diaz-Ortiz M; Liu B; Swanson CR; Skrinak RT; Hernandez-Con P; Amado DA; Fullard M; Rick J; Siderowf A; Weintraub D; McCluskey L; Trojanowski JQ; Dewey RB; Huang X; Chen-Plotkin AS
    PLoS Med; 2019 Oct; 16(10):e1002931. PubMed ID: 31603904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia.
    Tropea TF; Mak J; Guo MH; Xie SX; Suh E; Rick J; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Trojanowski JQ; Van Deerlin V; Chen-Plotkin AS
    Ann Neurol; 2019 Jun; 85(6):801-811. PubMed ID: 30973966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.
    Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M
    Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease.
    Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.
    Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E
    PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of cognitive impairment in an early stage Parkinson's disease cohort.
    Hu MT; Szewczyk-Królikowski K; Tomlinson P; Nithi K; Rolinski M; Murray C; Talbot K; Ebmeier KP; Mackay CE; Ben-Shlomo Y
    Mov Disord; 2014 Mar; 29(3):351-9. PubMed ID: 24395708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes.
    Jones JD; Uribe C; Bunch J; Thomas KR
    J Neurol; 2021 Jan; 268(1):337-345. PubMed ID: 32804281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson's Disease.
    Luo J; Wu H; Li J; Xian W; Li W; Locascio JJ; Pei Z; Liu G
    Mov Disord; 2022 Dec; 37(12):2386-2395. PubMed ID: 36087011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients.
    Sulzer P; Becker S; Maetzler W; Kalbe E; van Nueten L; Timmers M; Machetanz G; Streffer J; Salvadore G; Scholz E; Tkaczynska Z; Brockmann K; Berg D; Liepelt-Scarfone I
    J Neurol; 2018 Sep; 265(9):1976-1984. PubMed ID: 29936665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid communication: Preliminary validation of a telephone adapted Montreal Cognitive Assessment for the identification of mild cognitive impairment in Parkinson's disease.
    Benge JF; Kiselica AM
    Clin Neuropsychol; 2021 Jan; 35(1):133-147. PubMed ID: 32779959
    [No Abstract]   [Full Text] [Related]  

  • 13. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort.
    Hobson P; Meara J
    Int J Geriatr Psychiatry; 2015 Oct; 30(10):1048-55. PubMed ID: 25676160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog.
    Isella V; Mapelli C; Morielli N; Siri C; De Gaspari D; Pezzoli G; Antonini A; Poletti M; Bonuccelli U; Picchi L; Napolitano A; Vista M; Appollonio IM
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1160-3. PubMed ID: 24011719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
    Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
    Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease.
    Uysal-Cantürk P; Hanağası HA; Bilgiç B; Gürvit H; Emre M
    Eur J Neurol; 2018 Jan; 25(1):148-153. PubMed ID: 28941002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning trained with quantitative susceptibility mapping to detect mild cognitive impairment in Parkinson's disease.
    Shibata H; Uchida Y; Inui S; Kan H; Sakurai K; Oishi N; Ueki Y; Oishi K; Matsukawa N
    Parkinsonism Relat Disord; 2022 Jan; 94():104-110. PubMed ID: 34906915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1).
    Wilson H; Pagano G; Yousaf T; Polychronis S; De Micco R; Giordano B; Niccolini F; Politis M
    J Neural Transm (Vienna); 2020 Jan; 127(1):51-59. PubMed ID: 31853652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive function in the early phase of Parkinson's disease, a five-year follow-up.
    Domellöf ME; Ekman U; Forsgren L; Elgh E
    Acta Neurol Scand; 2015 Aug; 132(2):79-88. PubMed ID: 25644230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.